The association between dopaminergic therapies and circadian genetic markers in PD has not been investigated, but animal models have demonstrated increased mRNA levels of selected clock genes after application of D1 and D2 dopamine receptor agonists (67), while D2 dopamine antagonists blunted the rhythm of striatal PER2 (68). The gene discussed is CLOCK; the disease is Parkinson disease.